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Abstract
Background: Bax inhibitor-1 (BI-1) is an evolutionary conserved endoplasmic reticulum protein that, when 
overexpressed in mammalian cells, suppresses the apoptosis induced by Bax, a pro-apoptotic member of the Bcl-2 
family. The aims of this study were: (1) to clarify the role of intrinsic anti- and pro-apoptotic mediators, evaluating Bax 
and BI-1 mRNA and protein expressions in liver tissues from patients with different degrees of liver damage; (2) to 
determine whether HCV and HBV infections modulate said expression.
Methods: We examined 62 patients: 39 with chronic hepatitis (CH) (31 HCV-related and 8 HBV-related); 7 with cirrhosis 
(6 HCV-related and 1 HBV-related); 13 with hepatocellular carcinoma (HCC) [7 in viral cirrhosis (6 HCV- and 1 HBV-
related), 6 in non-viral cirrhosis]; and 3 controls. Bax and BI-1 mRNAs were quantified by real-time PCR, and BI-1 protein 
expression by Western blot.
Results: CH tissues expressed significantly higher BI-1 mRNA levels than cirrhotic tissues surrounding HCC (P < 0.0001) 
or HCC (P < 0.0001). Significantly higher Bax transcripts were observed in HCV-genotype-1-related than in HCV-
genotype-3-related CH (P = 0.033). A positive correlation emerged between BI-1 and Bax transcripts in CH tissues, even 
when HCV-related CH and HCV-genotype-1-related CH were considered alone (P = 0.0007, P = 0.0005 and P = 0.0017, 
respectively).
Conclusions: BI-1 expression is down-regulated as liver damage progresses. The high BI-1 mRNAs levels observed in 
early liver disease may protect virus-infected cells against apoptosis, while their progressive downregulation may 
facilitate hepatocellular carcinogenesis. HCV genotype seems to have a relevant role in Bax transcript expression.
Background
Hepatocellular carcinoma (HCC) is a late complication of
chronic viral hepatitis and derives both from the chronic
inflammatory process, with consequent free radical over-
expression [1], cytokines [2] and growth factors release
[3], and from the capacity of viral proteins to modulate
the proliferation and death of infected hepatocytes. It has
been indeed suggested that dysregulation of the apoptotic
process in infected cells might be crucial in favoring the
chronicity of infection, the failure of antiviral treatment
and neoplastic transformation [4]. Much attention has
recently been focused on the intrinsic pathways of the
apoptotic process, and in particular on Bax and Bax
inhibitor 1 (BI-1) [5,6].
Bax is a pro-apoptotic protein, a member of the Bcl-2
family that includes pro- and anti-apoptotic proteins
[7,8]. Bax-induced apoptosis is associated with a change
in Bax cellular localization, reflecting its ability to
undergo a change from a soluble to an integral membrane
conformation [9]. Indeed, Bax is usually found in the
cytosol but, when activated, it moves to the mitochondria
and induces cytochrome c release [10,11].
In the cytosol, Bax encounters different environmental
conditions (e.g. pH, ion concentrations, ATP, NADH,
oxygen and many other parameters) that may induce
changes in Bax structure, with loss of ability to access and
interact with other proteins. It has been shown that some
anti-apoptotic proteins may hijack Bax in the cytosol,
thus preventing Bax oligomerization in the mitochon-
drial outer membrane [12], which seems to be an impor-
t a n t  s t e p  i n  t h e  a c t i v a t i o n  o f  B a x ,  m a k i n g  t h e
mitochondrial membranes permeable and triggering the
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executive phase of the apoptotic process (with caspase 3
and caspase 9 activation) [13].
Other proteins may bind the active form of Bax in the
mitochondria, however, thereby preventing Bax oli-
gomerization and the subsequent cytochrome c release
(clusterin, Bcl-2). One such protein is Bcl-2, which may
bind Bax and form heterodimers, consequently inhibiting
Bax activity [14].
Human Bax inhibitor-1 has also been identified as a
suppressor of Bax-mediated cell death in yeast [15]. BI-1
is an anti-apoptotic integral membrane protein, located
mainly in the intracellular membranes of endoplasmic
reticulum (ER) [16]. Its over-expression in mammalian
cells suppresses apoptosis induced by Bax, staurosporine
and growth factor deprivation. BI-1 is presumably not
needed for the physiological regulation of developmental
programmed cell death, since the liver tissues of BI-1-
deficient mice are histologically normal [17]. The anti-
apoptotic mechanism of BI-1 involves the suppression of
Bax activation and translocation to mitochondria, pre-
serving the mitochondria membrane potential and mito-
chondrial morphology, and preventing the activation of
post-mitochondrial caspases. BI-1 function is also associ-
ated with the regulation of intracellular Ca2+ omeostasis
[18].
The anti-apoptotic efficiency of BI-1 is also confirmed
by the fact that BI-1 antisense oligonucleotide can pro-
mote apoptosis in some tumor lines [15]. Little is known
as yet about the BI-1 protein's functions in human liver
diseases.
Given the importance of the biological activities of Bax
and BI-1, the aims of this study were to establish whether
Bax and BI-1 are expressed differently in the various
stages of chronic liver damage, from chronic hepatitis to
HCC.
Methods
Patients
This study involved 62 patients.
A first group included 39 patients with chronic hepatitis
(CH): 31 HCV-related (10 females, 21 males; mean age
40.2 ± 12.2 years; range 20-67; HCV-genotypes: 18 HCV-
1, 6 HCV-2, 4 HCV-3, 3 HCV-4), and 8 HBV-related (1
female, 7 males; mean age 39.5 ± 10.7 years; range 28-56).
The second group included 7 cirrhotic patients (CIRR):
1 HBV-related (a 56-year-old female) and 6 HCV-related
(1 female, 5 males; mean age 44 ± 14.4 years; range 33-
69).
The third group consisted of 13 patients with HCC in
cirrhosis: 6 HCV-related (2 females, 4 males; mean age
56.8 ± 16.9 years; range 23-69) and 1 HBV-related (a 55-
year-old male); and 6 patients with HCC in non-virus-
related cirrhosis (2 females, 4 males; mean age 61.5 ± 8.5
years; range 46-72). As "control" specimens (Control),
liver biopsy samples from 3 patients who had undergone
c h o l e c y s t e c t o m y  w e r e  c o n s i d e r e d  ( 2  f e m a l e s ,  1  m a l e ;
mean age 44.6 ± 18.6 years; range 25-62).
The diagnosis of chronic HCV infection was obtained
on the basis of HCV-RNA positivity by polymerase chain
reaction (PCR), persistently abnormal transaminases for
at least 12 months, and a compatible histology. Histologi-
cal diagnoses were made by a single pathologist and
scored, according to Ishak's classification [19], in all
biopsy samples. Before biopsy, each patient was tested to
measure HCV antibodies.
All the following studies were performed prior to any
treatment.
All patients, Caucasian Mediterranean, enrolled in this
study , were recruited from the Department of Surgical
and Gastroenterological Sciences, Division of Gastroen-
terology, School of Medicine, University of Padua, Italy.
Informed consent was obtained from all patients and
the study protocol was approved by our Institute's Ethics
Committee.
Liver samples
During a US-guided procedure (with a 16-18 gauge mod-
ified Menghini needle), liver biopsies were obtained from
patients with chronic hepatitis or liver cirrhosis accord-
ing to a standard protocol. One part of the liver specimen,
at least 2 cm long, was used for diagnostic purposes while
the remainder was immediately frozen in liquid nitrogen
and stored at -80°C.
Tissue samples were obtained from HCC at the time of
surgical resection. Tumor tissues used for mRNA extrac-
tion were macroscopically selected in the middle of the
nodule. The corresponding non-cancerous tissues
(PHCC) were taken at least 1 cm (more where possible)
from the edge of the tumor in the resected specimen. To
check for any presence of infiltrating tumor cells, a slice
of the sample was fixed in buffered formaldehyde, stained
with hematoxylin and eosin and examined by the pathol-
ogist. In all cases, care was taken during the surgical pro-
cedure to avoid contamination between cancerous and
non-cancerous samples.
All surgical liver specimens were cut into small pieces,
immediately snap frozen in liquid nitrogen, then stored at
-80°C.
The routine histological analysis was done in blind
fashion by the pathologist. HCC lesions were classified as
well-, moderately- or poorly-differentiated according to
the Edmonson & Steiner criteria [20], grading the speci-
mens on the basis of the predominant findings.
Virological and biochemical assessments
In all HCV-infected patients, HCV-specific serum anti-
bodies were detected by enzyme immunoassay (EIA-II;
Ortho Diagnostic System) and confirmed by recombinantKotsafti et al. BMC Gastroenterology 2010, 10:35
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immunoblot assay (RIBA-II; Ortho Diagnostic System)
according to the manufacturer's instructions.
HCV RNA was detected with a standardized poly-
merase chain reaction (PCR) (Amplicor, Roche Diagnos-
tic Systems, Neuilly, France) in the total RNA extracted
from biopsies.
HCV genotype was determined by the Inno-Lipa II
HCV method (Innogenetics S.A., Gent Belgium). HCV
genotypes were classified as genotype 1, subtypes 1a and
1b, and the remaining subtypes of types 2, 3, and 4 were
pooled under each corresponding genotype.
HBV serum markers were tested by radio-immune
assay (RIA) (Abbott, Chicago-Illinois, USA), while HBV-
DNA was tested with a commercially-available fluid
phase hybridization assay (Abbott, Chicago-Illinois,
USA).
Data regarding transaminases were obtained.
RNA isolation
Total RNA was extracted from frozen hepatic tissue with
acid guanidium thiocyanate-phenol-chloroform accord-
ing to the Chomczynski and Sacchi method [21]. RNA
concentrations were quantified spectrophotometrically.
Integrity of the RNA sample was assessed by electropho-
resis on a 2% agarose gel (FMC Bio Product, Rockland,
ME, USA) containing ethidium bromide. The quality of
the RNA isolated was also assessed using the RNA 6000
Nano Assay and the Agilent 2100 bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA).
Reverse transcription
For the synthesis of complementary DNA (cDNA), 2 μg
of RNA were reverse transcribed in a final volume of 40
μl in the presence of 1X PCR buffer, 1 mM each of dNTPs
(dATP, dTTP, dCTP, dGTP), 1 U RNase inhibitor, 2.5 μM
random hexamers, and 2.5 U of murine leukemia virus
(Perkin Elmer, Foster City, CA, USA).
The reverse transcription reaction was completed at
25°C for 10 min, 42°C for 15 min and 99°C for 5 min, in a
Perkin Elmer GeneAmp PCR System 2400.
The cDNA was stored at -20°C.
Primers
Oligonucleotide primers were designed with the Primer
Express software rel. 1.0 (ABI/PE Applied Biosystems,
Foster City, CA, USA) and synthesized by Primm (San
Raffaele, Milano-Italy). Nucleotide sequences for the
sense and antisense primers used for real-time PCR were:
5'-CTTTTGCTTCAGGGTTTCATCC-3', 5'-TTGAGA-
CACTC GCTCAGCTTCT-3' for Bax [ENST00000
356483], and the length of this amplicon was 119 bp; 5'-
TCTATGCAAGTTTTGCCCTTTGTA-3', 5'-GCCAGC-
CTGAATGAAATGA-3' for BI-1 [ENST00000267115],
and the length of this amplicon was 84 bp; 5'-CCTG-
GCACCCAGCACAA-3', 5'-GCCGATCCACACGGAG-
TACT for β-actin [ENST00000158302], and the length of
this amplicon was 70 bp.
PCR product analysis
PCR products underwent vertical electrophoresis on a
0.75 mm thick, non-denaturing 6% acrylamide/bis-acryl-
amide gel with 5% glycerol. The silver-nitrate-stained
bands were scanned on a densitometer and image ana-
lyzer system (Quantity-one- BIO-RAD Hercules, CA,
USA).
DNA purification
Purified DNAs were obtained using the MinElute PCR
Purification Kit according to the manufacturer's protocol.
The concentration of the purified amplicons was quanti-
fied spectrophotometrically with the Biophotometer
6131 (Eppendorf, Hamburg, Germany) and the
PicoGreen ds-DNA quantitation reagent and kits.
Fluorescence was measured with the LS-5 Lumines-
cence Spectrometer (Perkin Elmer, Foster City, CA) using
480 nm excitation and 520 nm emission.
Quantitative absolute real-time PCR
Real-time PCR was conducted in an ABI 7900 Sequence
Detection System (Applied Biosystems, Foster City, CA,
USA) using SYBR Green I [22]. The reaction was
obtained on 96-well plates, in a 25 μL final volume con-
taining 1X TaqMan buffer, 5.5 mmol of MgCl2, 200 μmol
of nucleotides with dUTP, 0.25 U of AmpliTaq Gold Poly-
merase (SYBR Green Master Mix), 300 nM of each
primer and 200 ng of cDNA template. After one 2-min
step at 50°C and a second step at 95°C for 10 min, samples
underwent 45 cycles of 45 s at 94°C and then: 45 s at 60°C
for Bax and β-actin; 45 s at 62°C for BI-1. A final exten-
sion step was performed at 60°C for 10 min. All tests were
performed in triplicate. Samples in which the cDNA was
omitted were used as negative controls. All the technical
details of this method are given in Table 1.
Gene expression quantification
The amounts of mRNA in the unknown samples were
determined from the standard curves of the gene of inter-
est [23]. Standards curves were generated using serial
diluition (1:10) from 108 to 102 copies/μl of a reference
sample.
Data were expressed as the ratio of the transcript
amounts of the gene of interest to the β-actin transcript
used as housekeeping gene.
Western blot analysis
Total protein extracts were obtained by homogenizing
liver tissues with RIPA lysis buffer (20 mM TrisHCl pH
7.4, 150 mM NaCl, 5 mM ethylene diamine tetra-acetic
acid [EDTA], 1.5% Niaproof, 1 mM sodium orthovana-
date Na3VO4 0.1% sodium dodecyl sulfate [SDS]). ProteinKotsafti et al. BMC Gastroenterology 2010, 10:35
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concentration was determined using the RC DC Protein
Assay (Bio-Rad, Hercules, CA, USA). 40 μg of boiled pro-
teins were loaded onto the gel. Proteins were separated by
SDS-PAGE, transferred onto nitrocellulose membrane
(Hybond ECL, GE Healthcare, Buckinghamshire, UK)
and blocked with fat-free milk [5% in Tween-phosphate-
buffered saline (PBS)] for 1 h. Membranes were probed
with the primary mouse monoclonal antibody against
human BI-1 (1:200) and the primary mouse monoclonal
antibody against β-actin (1:1000) (Santa Cruz Biotechnol-
ogies, California, USA). After incubation with the sec-
ondary antibody (goat anti-mouse IgG, at a dilution of
1:10000), immunoreactive proteins were visualized by
chemiluminescence using SuperSignal WestPico Chemi-
luminescent Substrate (Pierce, Rockford, Illinois, USA)
and captured on X-ray film (Hyperfilm™ ECL, GE Health-
care, Buckinghamshire, UK). Molecular sizing was car-
ried out using the Full-Range Rainbow Molecular weight
Marker (GE Healthcare, Buckinghamshire, UK). Exposed
films were digitized and the bands were semi-quantita-
tively evaluated by densitometric analysis. BI-1 protein
expression levels were thus normalized to those of the
housekeeping gene, β-actin.
Statistical analysis
All results are given as mean values ± SD (standard devia-
tion). Statistical analyses were performed using the Stat-
Soft software, rel. 5.0 (Tulsa, OK, USA). Differences
between groups were analyzed with the Kruskal-Wallis
test or Mann-Whitney U test, as appropriate. Two-tailed
P value < 0.05 were deemed to be significant. The rela-
tionship between two variables was determined using
Pearson's correlation analysis, accepting a P < 0.05 as sig-
nificant.
Results
The BI-1 and Bax mRNA levels in the livers are shown in
Figure 1 and Figure 2 respectively.
BI-1 mRNA expression
As concerns BI-1 expression, a statistically significant dif-
ference (P < 0.0001 by Kruskal Wallis test) emerged
between the five groups considered (Control, CH, CIRR,
PHCC, HCC). CH tissues expressed the highest levels of
BI-1 mRNA (950.81 ± 348.6), significant higher than in
PHCC (543.1 ± 345.4; P < 0.0001) or HCC (365.92 ±
185.52; P < 0.0001) tissues (Figure 1A). CIRR expressed
the same amount of BI-1, whether it was associated with
HCC or not. There was no difference in BI-1 mRNA lev-
els between tissues with HCV versus HBV-related CH
(984.83 ± 365.33 vs 819.00 ± 250.72).
Statistically significant differences in BI-1 expression
were observed between CH HCV and PHCC HCV (p <
0.0001) and HCC HCV (p < 0.001) and between CIRR
HCV and HCC HCV (p = 0.041) (Figure 1B).
No statistically significant difference in BI-1 expression
was found in CH HCV tissues according to the genotype
(Figure 1C).
No difference between virus- and non virus-related
HCC was detected (data non shown).
Bax mRNA expression
Bax transcript levels did not differ significantly between
Control tissues (7.623 ± 5.5) and all the pathological tis-
sues considered (CH 6.618 ± 2.6; CIRR 6.808 ± 2.4; PHCC
7.029 ± 3.3; HCC 8.294 ± 4.4) (Figure 2A). Nor were there
any differences in CH according to its etiology (CH HCV
6.749 ± 2.8; CH HBV 6.111 ± 1.6). No differences in Bax
mRNA expression were found considering only HCV-
infected tissues (Figure 2B). When only cases of CH with
HCV-related hepatitis were considered, according to the
genotype involved, patients with HCV-genotype-1 infec-
tion showed a statistically higher Bax mRNA expression
than in patients with HCV-genotype-3 infection (7.620 ±
3.0 vs 4.605 ± 1.70, P = 0.033) (Figure 2C).
No difference between virus- and non virus-related
HCC was detected (data non shown).
Western blot
BI-1 protein expression was only evaluated in surgical
liver tissues from 15 HCC patients, both in the cancer
and in the surrounding cirrhotic tissue. Like the BI-1
mRNA transcripts, BI-1 protein expression did not differ
in these tissues (Figure 3).
Table 1: Characteristic values relating to the expression of each gene considered by Real time PCR
Gene Threshold Slope Efficiency
E = (10-1/slope)-1
R2 Range
(copies/μl)
β-actin (n.24) 0.078 -3.34 ± 0.03 98.37 ± 3.43 0.998 108-102
Bax (n.15) 0.104 -3.51 ± 0.05 94.67 ± 1.99 0.998 108-103
BI-1 (n.18) 0.144 -3.48 ± 0.03 93.48 ± 1.34 0.999 108-102
Threshold value, manually adjusted, was maintained for all the standard curve analyzed. Table report the mean ±SD of the slope and 
efficiency value relative to n. 24, 15 and 18 standard curves of β-actin, Bax and BI-1 respectivelly. Efficiency was calculated from the slope 
using the equation E = (10-1/slope) -1. The correlation coefficient (square values R2) and range of standard curves are also reported.Kotsafti et al. BMC Gastroenterology 2010, 10:35
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Correlations
A significant positive correlation emerged between BI-1
and Bax mRNA expression in CH tissues (r = 0.51; P =
0.0007) (Figure 4A). The correlations between BI-1 and
B a x  m R N A  e x p r e s s i o n  w e r e  a l s o  s i g n i f i c a n t  w h e n
patients with HCV-related CH (r = 0.59; P = 0.0005) (Fig-
ure 4B) or HCV-genotype-1-related CH (r = 0.68; P =
0.0017) (Figure 4C) were considered separately.
No correlation in CH with disease "activity" (AST/ALT
levels) was detected.
Discussion
This study sought possible differences in the expression
of the anti-apoptotic BI-1 and pro-apoptotic Bax factors
in liver tissues from patients with different severity of
liver damage, from chronic viral hepatitis to cirrhosis and
finally HCC, with a view to examining its biological role
Figure 1 BI-1 mRNA analysis by quantitative absolute real-time 
PCR using SYBR Green I: in control specimens (Control), liver sam-
ples from patients with chronic hepatitis (CH), cirrhosis (CIRR), cir-
rhotic tissues surrounding hepatocellular carcinoma (PHCC) and 
HCC (1A); in HCV-infected liver tissues (1B); in CH HCV-related tis-
sues according to genotypes (1C). The unknown BI-1 and β-actin 
mRNA amounts in the samples were extrapolated by the respective 
standard curves performed using serial diluition (1:10) from 108 to 102 
copies/μl of a reference sample. Form each sample the normalized 
amount of the BI-1 transcripts was obtained by the ratio of BI-1 to β-
actin, used as housekeeping gene. Data are expressed as mean values 
± SD.
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Figure 2 Bax mRNA analysis by quantitative absolute real-time 
PCR using SYBR Green I: in control specimens (Control), liver sam-
ples from patients with chronic hepatitis (CH), cirrhosis (CIRR), cir-
rhotic tissues surrounding hepatocellular carcinoma (PHCC) and 
HCC (2A); in HCV-infected liver tissues (2B); in CH HCV-related tis-
sues according to genotypes (2C). The unknown Bax and β-actin 
mRNA amounts in the samples were extrapolated by the respective 
standard curves performed using serial diluition (1:10) from 108 to 102 
copies/μl of a reference sample. Form each sample the normalized 
amount of the BI-1transcripts was obtained by the ratio of Bax to β-ac-
tin, used as housekeeping gene. Data are expressed as mean values ± 
SD.
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in the progression of liver disease towards cancer, natu-
rally history in which little is known about the expression
of BI-1 and Bax.
Bax mRNA transcripts were much the same in the nor-
mal, cirrhotic, and HCC tissues analyzed, suggesting that
the presence of a constitutive expression of Bax in the
liver is not significantly up- or down-regulated during the
progression of liver diseases. Bax has not always been
found located in the cytosol, however, and a constitutive
mitochondrial location of Bax in healthy cells has been
described both in cell culture [24] and in experimental
animals, in different organs [16,17]. Moreover, the activa-
tion of Bax during apoptosis does not usually require an
increase in this gene transcription. These findings are
consistent with our results and suggest that Bax mRNA
levels are not differently modulated in normal (even
though the number of "control" subjects in our series is
limited) and diseased livers, so they do not change with
the progression of chronic liver damage. Bax transcripts
however, seems to be modulated by the HCV genotype, at
least judging from the greater increase of Bax in HCV-
genotype-1-related CH as compared with HCV-geno-
type-3-related CH.
Activation and functioning of Bax is a complex process.
Many recent studies have described the conformation of
native cytosolic Bax and how the Bax protein can interact
with other proteins undergoing conformational modifica-
tions (such as the switch from a cytosolic to a mitochon-
drial, membrane-insert protein) during apoptosis [25].
Inside the cell, Bax is subject to the effect of many envi-
ronmental factors, which vary in time, slightly loosening
the globular structure and allowing protein-protein inter-
action. Under physiological conditions, this loosening of
the structure may be an early event that is necessary but
not sufficient to induce a transition in Bax conformation.
The binding of additional membrane compounds or
other BH3-containing proteins might be the determining
event that triggers the conformational change [12,26].
Figure 3 BI-1 protein expression in HCC and tissues surrounding 
HCC. (3A): Western blot analysis of BI-1 protein expression in cirrhotic 
liver tissues surrounding hepatocellular carcinoma (PHCC) and in HCC 
tissues obtained from the same patient. Proteins were loaded onto 
15% SDS-polyacrylamide gels and transferred to nitrocellulose mem-
branes. Blots were incubated with anti-BI-1 and anti β-actin antibodies, 
followed by detection using an ECL method. (3B): Results of the den-
sitometric analysis of BI-1. Data are expressed as the optical density ra-
tio of BI-1 to β-actin. Values are reported as mean values ± SD.
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Figure 4 Results of the linear regression analysis in tissues from 
patients with CH. (4A): Linear regression analysis of BI-1/β-actin vs 
Bax/β-actin in all CH tissues; (4B): in HCV infected CH tissues; (4C): in 
HCV-genotype-1-related CH.
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Bax is actually a multidomain protein containing the
BH-1, BH-2 and BH-3 domains, so it may form com-
plexes such as: Bax/Bax, Bax/Bcl-2, Bax/BclXL and thus
drive a different (pro or anti) intracellular apoptotic path-
way activation [27]. A reduced Bax expression has been
described in many human diseases, primarily tumors,
such as in ovarian [28] and cervical cancer [29] a fact that,
at least in our experience is not confirmed in HCC.
Conversely, we found that BI-1 mRNA transcripts
dropped significantly with the progression of liver dam-
age from CH to cirrhosis and HCC, suggesting a crucial
role for BI-1 in regulating the apoptotic pathways, partic-
ularly in early liver disease. The drop in BI-1 involved
similarly both HCC and the cirrhotic tissues surrounding
the tumor, thus indicating the presence of a "field defect"
that involves also virus- and non virus-related HCC. BI-1
is an integral membrane protein localized in ER mem-
branes and protects cells from apoptosis induced by ER
stress. Acute and chronic liver diseases are characterized
by inflammatory processes with enhanced expression of
various pro- and anti-inflammatory cytokines, toxic
metabolites, ROS (reactive oxygen species) and bile acids.
Therefore the increase of BI-1 mRNA expression may
represent a protective effect with respect to the virus-
induced inflammatory response.
The mechanism by which BI-1 regulates ER Ca++ fluxes
remains unclear. Recently it was demonstrated that the
effect of BI-1 on ER Ca++ permeability is pH-dependent.
Acidic condition promotes BI-1 oligomerization inducing
the creation of Ca++ channel and consequent Ca++ release
from ER [30].
BI-1 is also a critical regulator of ER stress response in
the development of obesity-associated insulin resistance,
as reported by Bailly-Maitre B et al. [31]. The study of BI-
1 expression in NAFLD (Non-Alcoholic Fatty Liver Dis-
ease) could be important to understand its molecular
function also in metabolic disorders.
In liver cancer inflammatory cells colonize the liver and
we also demonstrated, in a previous study, increased
proinflammatory cytokines mRNA levels and lympho-
cytes and monocytes/macrophages density in tissues sur-
rounding primary and secondary liver tumors [32]. These
cells have an important role in inducing a pH reduction.
Therefore the low BI-1 mRNAs expression found in HCC
seems be also related to the decrease of inflammatory
response and consequently to the local alkalinization.
It is well known that liver cell proliferation increases
during chronic hepatitis while an impaired hepatocyte
proliferation at the cirrhosis stage leads to a further selec-
tion of genetically altered, hyper-proliferating, pre-malig-
nant clone of transformed hepatocytes and then tumor
formation. In this scenario apoptosis is, in HCV-related
hepatitis, relatively down-regulated with respect to the
increased cell proliferation [33]. Also, in an our previous
study, TUNEL analysis revealed a decrease of the number
of apoptotic cells in HCC [34]. Therefore the low BI-1
mRNA expression showed in our HCC and peritumoral
tissues in this study, with no difference between the two
as confirmed by western blotting, support previous find-
ings and may contribute to the carcinogenetic process
through the inhibition of the apoptotic process, favoring
tumor progression.
The statistically significant differences found in HCV
tissues points to an involvement of viral proteins, and
pa rt i cu la r l y  t h e  p r o t e i n s  o f  t h e  C  vi ru s  g e n o t ype  1 ,  i n
modulating the apoptotic pathway. HCV has developed a
range of mechanisms for evading the cell's defenses,
modulating the apoptosis of infected cells as, for instance,
the interaction with PKR (a dsRNA-dependent protein
kinase).
NS5A (non-structural 5A) and E2 (envelope) HCV pro-
teins may bind to and inactivate PKR [35,36]. This seems
more evident in genotype 1 variant by the greatest
homology found between E2 and PKR compared to the
other genotypes.
The higher Bax levels found in HCV genotype 1 may be
therefore indicative of an additional signaling pathway
independent of PKR; for instance, the association of
NS5A with the ER and Golgi [37] may represent an alter-
native pathway involved in Bax activation.
Conclusion
The BI-1 expression decrease correlates closely with the
progression of liver disease from CH to cirrhosis and
then to HCC in HCV-infected tissues, suggesting a clear
role of viral proteins in the induction of relevant event for
liver damage. Therefore this down-regulation of BI-1
observed both in HCC and in the cirrhotic tissue sur-
rounding the tumor, may well contribute to hepatocellu-
lar carcinogenesis and tumor progression. The lack of a
difference between BI-1 expression in virus- versus non
virus-related HCC points to a "field defect" not related to
disease etiology. A deeper understanding of BI-1 and Bax
expression, modulation and interaction with other factors
involved in the apoptotic pathways could prove useful for
the development of new approaches to the prevention
and the treatment of liver cancer.
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